Literature DB >> 11296978

Cost assessment instrument in rheumatology: evaluation of applied instrument characteristics.

J Ruof1, S Merkesdal, J L Huelsemann, O Schoeffski, A Maetzel, W Mau, H Zeidler.   

Abstract

We compared the major characteristics of internationally applied cost assessment instruments (CAI) in rheumatic conditions. Fifteen utilization questionnaires were identified and assessed using a structured approach. The forms differed considerably with respect to applied characteristics: length (3-113 items), recall period (between 1 week and 1 year), format (2 interview, 13 self-administered), response categories, cost units (physical vs monetary), and cost domains covered. While all included a gross assessment of outpatient and inpatient costs, the level of disaggregation differed. Only a few CAI included an assessment of other direct disease related costs (e.g., home remodeling or home health care services) and out-of-pocket expenditure. Productivity costs were included in all but 2 CAI. Efforts to further standardize the applied CAI should (1) be based on sound psychometric data, (2) define a required core set of cost domains covered, (3) discriminate between generic and relevant disease related cost components, and (4) examine the feasibility of developing international standards for cost data.

Entities:  

Mesh:

Year:  2001        PMID: 11296978

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

1.  [Conceptual and methodological basics of cost assessments in rheumatology].

Authors:  J Ruof; J L Hülsemann; T Mittendorf; J-M von der Schulenburg; H Zeidler; S Merkesdal
Journal:  Z Rheumatol       Date:  2004-10       Impact factor: 1.372

Review 2.  International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review.

Authors:  Hubertus Rosery; Rito Bergemann; Stefanie Maxion-Bergemann
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study'.

Authors:  J L Hülsemann; J Ruof; H Zeidler; T Mittendorf
Journal:  Rheumatol Int       Date:  2005-11-01       Impact factor: 2.631

4.  Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries.

Authors:  A Boonen; D van der Heijde; R Landewé; F Guillemin; M Rutten-van Mölken; M Dougados; H Mielants; K de Vlam; H van der Tempel; S Boesen; A Spoorenberg; H Schouten; Sj van der Linden
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

5.  Comparison of estimated medical costs among patients who are defined as having rheumatoid arthritis using three different standards.

Authors:  Jörg Ruof; Jan L Hülsemann; Thomas Mittendorf; Silke Handelmann; Rick Aultman; J Matthias von der Schulenburg; Henning Zeidler; Sonja Merkesdal
Journal:  Eur J Health Econ       Date:  2004-02

6.  The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study.

Authors:  A Maetzel; L C Li; J Pencharz; G Tomlinson; C Bombardier
Journal:  Ann Rheum Dis       Date:  2004-04       Impact factor: 19.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.